Sanofi and Regeneron Pharmaceuticals have announced results from the Phase III trial of sarilumab in adult patients with active rheumatoid arthritis (RA) who were inadequate responders to methotrexate (MTX) therapy. The treatment, in combination with MTX, improved disease signs and symptoms as well as physical function, and inhibited progression of joint damage. The 52-week trial enrolled approximately 1,200 patients with active, moderate-to-severe RA, who were inadequate responders to MTX ther...